PCSK9 and coronary artery disorder: This is important as on-going phase III clinical trials of PCSK9 inhibitory monoclonal antibodies (e.g. evolocumab in NCT01764633; RN316 in NCT01975389 and NCT01975376; and, alirocumab in NCT01617655) and APOB mRNA antisense oligonucleotide inhibitor (mipomersen in NCT01475825) will most likely show beneficial effects on major clinical outcomes [as evidenced by strong genetic associations with CAD and extremely encouraging findings from large, individual (Koren et al. 2014) and pooled analysis of phase II RCTs of PCSK9 inhibition (Stein et al. 2014)].